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The existence of two receptors for estrogen, ERα and ERβ, en-
coded by two different genes (ESR1 and ESR2), together with
the existence of its isoforms and splice variants, imposes the
need to clarify their function in estrogen signaling. In order to
investigate if the weight ratio of estrogen receptor beta (ERβ1)
and its splice variant (ERβΔ5) is different in malignant tissue
compared to healthy tissue we analyzed their expression by the
method of quantitative RT-PCR and showed that ratio
ERβ1/ERβΔ5 in breast cancer and cell line MDA MB 361 is in-
creased compared to healthy tissues. This finding suggests that
decreasing of ERβΔ5 may be one of the phenomena related to
tumorigenesis in estrogen responsive tissues and points to pos-
sible application of this type of analysis in future standard clin-
ical practice
The status of estrogen receptor alpha (ERα) and that of
progesterone receptor (PR) are routinely used in breast cancer
treatment to select optimal therapy. Overall, approximately
60% of ERα-positive tumors respond to endocrine therapies.
Although combination of ERα with PR level determination of-
fers some improvement in the prediction of endocrine response,
it still does not serve as an absolute predictor of responsiveness
to endocrine therapy. Identification of the second estrogen re-
ceptor, named estrogen receptor beta (ERβ), as well as the exis-
tence of numerous isoforms/splice variants of both ERα and
ERβ, suggests that complex regulation of estrogen function ex-
ists. After the cloning and characterization of ERβ, several iso-
forms and splice variants at the mRNA level were described but
their biological significance has not yet been resolved. Deletion
of one or more coding exons was among the first recognized
mechanisms for generation of splice variants (V l a d u š i ć et
al., 1998; L u et al., 1998; P o o l a et al., 2002). The splice
variant without the fifth exon (ERβΔ5), which encodes truncat-
ed protein, was one of first recognized deletion variants of the
ERβ transcripts, but little is known about its expression level in
cancer. We propose that two mRNA transcripts of ERβ, viz., β1
encoding wild type receptor and Δ5, are differentially expressed
in malignant and normal cells. In light of the fact that inhibito-
ry activity of ERβΔ5 seems to be dose-dependent, we quanti-
fied the mRNA level of these two transcripts (ERβ1 and ER-
βΔ5) in normal and malignant tissues and in malignant cell
lines. In this study, we analyzed the wight ratio isoform ERβ1
and ERβΔ5 mRNA. Here analyzed normal and breast carcino-
ma tissue (BC) and MDA MB 361 (a cell line from human
breast adenocarcinoma), as well as normal testicular and uterine
tissue. Expression of ERβ1 and ERβΔ5 was measured using
sensitive and specific TaqMan probes by the method of quanti-
tative RT-PCR. 
Analysis was perform on 34 samples obtained after surgery
from patients with primary breast tumors hospitalized at the In-
stitute of Oncology and Radiology of Serbia, Belgrade. These
samples were chosen as positive for ERβ1 mRNA expression
based on the cut-off value established in our previous study
(M a n d u š i ć et al., 2006). Samples of adjacent normal tis-
sues were obtained after total mastectomy. Samples of testicu-
lar tissue were obtained from the Institute of Pathology, Bel-
grade, while samples of uterus were obtained from patients who
underwent hysterectomy at the Institute of Obstetrics and Gyne-
cology in Belgrade. Tissue was stored on liquid nitrogen until
RNA isolation. All patients met the following criterion: prima-
ry operable unilateral invasive breast carcinomas without previ-
ous treatment. The study was approved by the Institutional Re-
view Board and adhered to the National Health Regulation
Guidelines. Approximately 50 – 100 mg of tissue frozen in liq-
uid nitrogen was pulverized in a cold mortar and extraction of
total RNA was performed by the acid-phenol guanidine method
according to C h o m c z y n s k i and S a c c i (1987). Quality
and concentration of the RNA preparation were verified on
0,8% agarose gels stained with ethidium bromide. One μg of to-
tal RNA was reverse-transcribed over a period of 60 min at
37ºC in a reaction volume of 20μl with the Omniscript RT Kit
(Qiagen, Hilden, Germany) using the 10-μM random hexamer
and 1-μM oligodT(15) primer according to manufacturer in-
structions. All PCR reactions were performed using a 7000 Se-
quence Detection System (Applied Biosystems, Foster City,
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CA). PCR was carried out in 25-µl reaction volume containing
the 1x TaqMan Universal PCR Master Mix, 1x TaqMan Pre-De-
signed Gene Expression Assay (Applied Biosystems, Foster
City, CA) and 10 μl of cDNA diluted with water (1:10). Assays
were specific for target transcripts: assay ID Hs01100359_m1
for ERβ1 and assay ID Hs01105521_m1 for ERβΔ5. The ratio
of examined transcripts ERβ1 and ERβΔ5 in each sample was
expressed as N-fold differences relative to each other according
to the equation: N = 2-(CtERβ1 – CtERΔ5), where Ct is the thresh-
old cycle. Differences in expression of ratio ERβ1/ERβΔ5 be-
tween healthy breast tissue and either BC or the MDA MB 361
cell line were analyzed by the Mann-Whitney and t- test, re-
spectively. 
The ratio of ERβ1 and ERβΔ5 mRNA was expressed as the
N-fold difference in the relation to each other in examined sam-
ples. Expression of ratio ERβ1/ERβΔ5 in normal breast tissue is
significantly lower than in BC (p = 0,016, Mann-Whitney, Fig.
1). In addition, expression of ratio ERβ1/ERβΔ5 in the adeno-
carcinoma cell line significantly differs from that in normal
breast tissue (p < 0,001, t-test) and is similar to that found in
BC. Normal uterine and testicular tissue as a control did not sig-
nificantly differ from normal breast tissue regarding the
ERβ1/ERβΔ5 ratio (Fig. 1).
These data suggest that an increased relative weight ratio
of receptor ERβ1 and truncated receptor ERβΔ5 is connected
with the process of malignant transformation. Increase of ratio
ERβ1/ERβΔ5 in BC results mainly from more pronounced de-
crease of ERβΔ5 mRNA expression than of ERβ1 mRNA ex-
pression in breast tumors compared to normal breast tissue. We
have shown (M a n d u š i ć et al., 2007) decrease of both ERβ1
and ERβΔ5 mRNA expression in breast tumors compared to
normal breast tissue. Protein encoded by ERβΔ5 mRNA lacks
the C terminal domain (responsible for ligand binding) but re-
tains the domains for nuclear localization and heterodimeriza-
tion. Such a receptor could, potentially, have an effect on tran-
scriptional activities of both estrogen receptors, ERα and ERβ.
It has been shown that ERβΔ5 protein in a cell transfection sys-
tem attenuates E2-stimulated transactivation by ERβ1 and ERα
in a dose-dependant manner (I n o u e et al., 2000). In contrast,
ERβΔ5 alone lacks transcriptional activity even in the presence
of a ligand (I n o u e et al., 2000). It follows that the ERβΔ5 re-
ceptor acts as an inhibitor of transcriptional activity of weight
isoforms of ERα and ERβ. This means that decrease in inhibi-
tory activity of ERβΔ5 during estrogen-stimulated proliferation
may be involved in tumorigenesis. In conclusion, we point out
the need to analyze the complete isoform profiles of ERβ, Erα,
and PR in clinical samples, since it is possible that the pattern
of isoform expression might be of prognostic and predictive
value in clinics.
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Fig. 1. Ratio of ERβ1/ERβΔ5 in normal tissue (NB - breast, T - testis, U – uterus), malignant tissue (BC - breast carcinomas), and an adenocarcino-
ma cell line (MDA mb 361). The Y axis represents relative expression ratio of two transcripts, ERβ1 and ERβΔ5, obtained from Ct values as described
in the text. 
